الولايات المتحدة · مجلات اقتصادية · Markets Insider (Business Insider)

Leads Biolabs' LBL-034 Shows 21.8-Month Median PFS in First-in-Human RRMM Data at ESMO 2026, Validating Its Proprietary TCE Platform

نشره Markets Insider (Business Insider) · الولايات المتحدة منذ 3 س

NANJING, China, Oct. 25, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (âLeads Biolabsâ, Stock Code: 9887.HK) today announced updated firstâinâhuman clinical…

اقرأ المقال كاملًا على Markets Insider (Business Insider) سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (markets.businessinsider.com)

يستحق القراءة أيضًا

Fortune

‘Everyone is hedging.’ As the U.S. and China divide the world into rival AI blocs, that lends power to ‘swing countries’ in between

Inc.

Think Being a Night Owl Is Just a Sleep Preference? Researchers Link It to a Depression Subtype

Kiplinger

Leads Biolabs' LBL-034 Shows 21.8-Month Median PFS in First-in-Human RRMM Data at ESMO 2026, Validating Its Proprietary TCE Platform

مشاركة

يستحق القراءة أيضًا

‘Everyone is hedging.’ As the U.S. and China divide the world into rival AI blocs, that lends power to ‘swing countries’ in between

Think Being a Night Owl Is Just a Sleep Preference? Researchers Link It to a Depression Subtype

Can a Roth Conversion Wait if You're 5-10 Years From Retiring?

Look up tonight: October’s full moon is for hunters

Millennials are having their midlife career crisis

Carson Hocevar Is Telling NASCAR Fans To Vote For Somebody Else